Abstract: Provided are pharmaceutical compositions comprising alpha-2-macroglobulin (A2M) and a serine protease protein such as porcine pancreatic elastase (PPE), which are bound together in a protein complex that retains the CD95 protease cleavage and cancer-cell killing activities of the serine protease, but sterically hinders binding of the serine protease to fibrinogen and serine protease inhibitors; and related methods of use and manufacture for treating diseases such as cancers.

Abstract: Embodiments of the current invention provide a solution to the problems associated with balancing patient toxicity with broad efficacy of cancer therapy. In particular, embodiments are directed to anti-cancer peptides that demonstrate a broad anti-cancer efficacy with a limited toxicity to normal or non-cancer cells.

Abstract: Provided is a membrane for cell culture and differentiation. The membrane comprises a base portion and an array of protrusions consisting of a plurality of protrusions. The protrusions are substantially evenly distributed on the base portion. The plurality of protrusions has dimensions on the order of micrometers. In particular, the membrane consists of particles of different particle sizes of two or more types. One type of particles has an average particle size of 1 ?m to 50 ?m. Two or more types of particles of different particle sizes include nanoscale particles, 10-900 nm. One type of particle is selected from the group consisting of inorganic compound microspheres. The other type of particles of the two or more types of particles of different particle sizes is selected from the group consisting of organic polymer nanospheres. Also provided is a method for maintaining, culturing and/or differentiating cells using such membrane.

Abstract: Embodiments are directed to: (i) neutrophil secreted factors that have the capacity to kill a broad range of cancer cells without affecting the viability of non-cancer cells. Two neutrophil killing factors have been identified by the inventors: (1) eosinophil cationic protein (ECP) and (2) neutrophil elastase (ELANE); or (ii) therapeutic compositions that include CD95 degrading polypeptide components and methods of treating cancer with the same.

Abstract: Embodiments of the current invention provide a solution to the problems associated with balancing patient toxicity with broad efficacy of cancer therapy. In particular, embodiments are directed to anti-cancer peptides that demonstrate a broad anti-cancer efficacy with a limited toxicity to normal or non-cancer cells.

Abstract: Embodiments are directed to: (i) neutrophil secreted factors that have the capacity to kill a broad range of cancer cells without affecting the viability of non-cancer cells. Two neutrophil killing factors have been identified by the inventors: (1) eosinophil cationic protein (ECP) and (2) neutrophil elastase (ELANE); or (ii) therapeutic compositions that include CD95 degrading polypeptide components and methods of treating cancer with the same.

Abstract: This disclosure relates to nucleic acid-derivatized therapeutics and methods of their use.

Abstract: Provided is a membrane for cell culture and differentiation. The membrane comprises a base portion and an array of protrusions consisting of a plurality of protrusions. The protrusions are substantially evenly distributed on the base portion. The plurality of protrusions has dimensions on the order of micrometers. In particular, the membrane consists of particles of different particle sizes of two or more types. One type of particles has an average particle size of 1 ?m to 50 ?m. Two or more types of particles of different particle sizes include nanoscale particles, 10-900 nm. One type of particle is selected from the group consisting of inorganic compound microspheres. The other type of particles of the two or more types of particles of different particle sizes is selected from the group consisting of organic polymer nanospheres. Also provided is a method for maintaining, culturing and/or differentiating cells using such membrane.

Abstract: Embodiments of the current invention provide a solution to the problems associated with balancing patient toxicity with broad efficacy of cancer therapy. In particular, embodiments are directed to anti-cancer peptides that demonstrate a broad anti-cancer efficacy with a limited toxicity to normal or non-cancer cells.

Abstract: Embodiments are directed to: (i) neutrophil secreted factors that have the capacity to kill a broad range of cancer cells without affecting the viability of non-cancer cells. Two neutrophil killing factors have been identified by the inventors: (1) eosinophil cationic protein (ECP) and (2) neutrophil elastase (ELANE); or (ii) therapeutic compositions that include CD95 degrading polypeptide components and methods of treating cancer with the same.

Abstract: Provided is a membrane for cell culture and differentiation. The membrane has a base portion and an array of protrusions consisting of a plurality of protrusions. The protrusions are substantially evenly distributed on the base portion. The plurality of protrusions has dimensions on the order of micrometers. In particular, the membrane consists of particles of different particle sizes of two or more kinds. One kind of particles have an average particle size of 1 ?m to 50 ?m. Two or more kinds of particles of different particle sizes include nanoscale particles, 10-900 nm. One kind of particles are selected from the group consisting of inorganic compound microspheres. The other kind of particles of the two or more kinds of particles of different particle sizes are selected from the group consisting of organic polymer nanospheres. Also provided is a method for maintaining, culturing and/or differentiating cells using such membrane.